{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:51:33Z","timestamp":1792759893547,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ejps.2021.106020","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T06:50:29Z","timestamp":1632725429000},"page":"106020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Preparation and characterization of a naringenin solubilizing glycyrrhizin nanomicelle ophthalmic solution for experimental dry eye disease"],"prefix":"10.1016","volume":"167","author":[{"given":"Qiqi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianggen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.106020_bib0001","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/250230","article-title":"Efficacy of topical mesenchymal stem cell therapy in the treatment of experimental dry eye syndrome model","volume":"2014","author":"Beyazyildiz","year":"2014","journal-title":"Stem. Cells Int."},{"key":"10.1016\/j.ejps.2021.106020_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13020291","article-title":"Naringenin nano-delivery systems and their therapeutic applications","volume":"13","author":"Bhia","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2021.106020_bib0003","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/eye.2017.289","article-title":"Assessment and management of dry eye disease","volume":"32","author":"Buckley","year":"2018","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.ejps.2021.106020_bib0004","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.2147\/OPTH.S186074","article-title":"Efficacy and safety of glycyrrhizin 2.5% eye drops in the treatment of moderate dry eye disease: results from a prospective, open-label pilot study","volume":"12","author":"Burillon","year":"2018","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.ejps.2021.106020_bib0005","doi-asserted-by":"crossref","first-page":"e26103","DOI":"10.1371\/journal.pone.0026103","article-title":"Corneal alternations induced by topical application of benzalkonium chloride in rabbit","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejps.2021.106020_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153375","article-title":"Naringenin protects RPE cells from NaIO3-induced oxidative damage in vivo and in vitro through up-regulation of SIRT1","volume":"80","author":"Chen","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejps.2021.106020_bib0007","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.ijbiomac.2020.07.306","article-title":"Polypeptide and glycosaminoglycan polysaccharide as stabilizing polymers in nanocrystals for a safe ocular hypotensive effect","volume":"162","author":"Donia","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejps.2021.106020_bib0008","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.37765\/ajmc.2021.88625","article-title":"Evolving knowledge of the unmet needs in dry eye disease","volume":"27","author":"Dunn","year":"2021","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.ejps.2021.106020_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119313","article-title":"Delineating penetration enhancer-enriched liquid crystalline nanostructures as novel platforms for improved ophthalmic delivery","volume":"582","author":"El-Gendy","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.106020_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13030360","article-title":"Cyclosporine Lipid Nanocapsules as Thermoresponsive Gel for Dry Eye Management: promising Corneal Mucoadhesion, Biodistribution and Preclinical Efficacy in Rabbits","volume":"13","author":"Eldesouky","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2021.106020_bib0011","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1167\/iovs.05-0495","article-title":"Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance","volume":"47","author":"Enriquez de Salamanca","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejps.2021.106020_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12040306","article-title":"Gelatin Nanoparticles-HPMC hybrid system for effective ocular topical administration of antihypertensive agents","volume":"12","author":"Esteban-Perez","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2021.106020_bib0013","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/OPX.0b013e3182348c28","article-title":"Comparison of three lubricant eye drop solutions in dry eye patients","volume":"88","author":"Evangelista","year":"2011","journal-title":"Optom. Vis. Sci."},{"key":"10.1016\/j.ejps.2021.106020_bib0014","doi-asserted-by":"crossref","first-page":"29753","DOI":"10.1038\/srep29753","article-title":"Intranasal delivery of nanomicelle curcumin promotes corneal epithelial wound healing in streptozotocin-induced diabetic mice","volume":"6","author":"Guo","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2021.106020_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108364","article-title":"Expression profiles and potential corneal epithelial wound healing regulation targets of high-mobility group box 1 in diabetic mice","volume":"202","author":"Hou","year":"2021","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejps.2021.106020_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2021.108454","article-title":"Glycyrrhizin micelle as a genistein nanocarrier: synergistically promoting corneal epithelial wound healing through blockage of the HMGB1 signaling pathway in diabetic mice","volume":"204","author":"Hou","year":"2021","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejps.2021.106020_bib0017","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.2147\/IJN.S127683","article-title":"A review of drug delivery systems based on nanotechnology and green chemistry: green nanomedicine","volume":"12","author":"Jahangirian","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejps.2021.106020_bib0018","article-title":"Effects of subconjunctival administration of anti-high mobility group box 1 on dry eye in a mouse model of Sjgren\u2019s syndrome","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejps.2021.106020_bib0019","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1167\/iovs.17-23363","article-title":"High-Mobility Group Box 1 in Dry Eye Inflammation","volume":"59","author":"Lema","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejps.2021.106020_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108113","article-title":"The effect of astaxanthin on inflammation in hyperosmolarity of experimental dry eye model in vitro and in vivo","volume":"197","author":"Li","year":"2020","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejps.2021.106020_bib0021","first-page":"257","article-title":"A mouse dry eye model induced by topical administration of benzalkonium chloride","volume":"17","author":"Lin","year":"2011","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ejps.2021.106020_bib0022","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ijpharm.2018.06.025","article-title":"Visual validation of the measurement of entrapment efficiency of drug nanocarriers","volume":"547","author":"Lv","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.106020_bib0023","doi-asserted-by":"crossref","DOI":"10.1111\/aos.14714","article-title":"Oxidative and antioxidative stress markers in dry eye disease: a systematic review and meta-analysis","author":"Navel","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ejps.2021.106020_bib0024","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1167\/iovs.16-19702","article-title":"Naringenin Eye Drops Inhibit Corneal Neovascularization by Anti-Inflammatory and Antioxidant Mechanisms","volume":"58","author":"Oguido","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejps.2021.106020_bib0025","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1002\/ptr.6178","article-title":"Liquorice (Glycyrrhiza glabra): a phytochemical and pharmacological review","volume":"32","author":"Pastorino","year":"2018","journal-title":"Phytother. Res."},{"key":"10.1016\/j.ejps.2021.106020_bib0026","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1167\/iovs.19-26928","article-title":"Therapeutic effects of STAT3 inhibition on experimental murine dry eye","volume":"60","author":"Qu","year":"2019","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejps.2021.106020_bib0027","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/NHH.0000000000000652","article-title":"Dry eye disease: prevalence, assessment, and management","volume":"36","author":"Rouen","year":"2018","journal-title":"Home Healthc Now"},{"key":"10.1016\/j.ejps.2021.106020_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120640","article-title":"Formulation development and upscaling of lipid nanocapsules as a drug delivery system for a novel cyclic GMP analogue intended for retinal drug delivery","volume":"602","author":"Urimi","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.106020_bib0029","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.toxlet.2019.10.014","article-title":"Benzalkonium chloride-induced direct and indirect toxicity on corneal epithelial and trigeminal neuronal cells: proinflammatory and apoptotic responses in vitro","volume":"319","author":"Vitoux","year":"2020","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.ejps.2021.106020_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.110926","article-title":"Novel self-nanomicellizing formulation based on rebaudioside A: a potential nanoplatform for oral delivery of naringenin","volume":"112","author":"Wang","year":"2020","journal-title":"Mater. Sci. Eng. C Mater Biol. Appl."},{"key":"10.1016\/j.ejps.2021.106020_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119133","article-title":"Nanocomplexes based polyvinylpyrrolidone K-17PF for ocular drug delivery of naringenin","volume":"578","author":"Wang","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.106020_bib0032","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.carbpol.2016.04.115","article-title":"Preparation and evaluation of naringenin-loaded sulfobutylether-beta-cyclodextrin\/chitosan nanoparticles for ocular drug delivery","volume":"149","author":"Zhang","year":"2016","journal-title":"Carbohydr. Polym."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721003237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721003237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:02:22Z","timestamp":1760529742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721003237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":32,"alternative-id":["S0928098721003237"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.106020","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preparation and characterization of a naringenin solubilizing glycyrrhizin nanomicelle ophthalmic solution for experimental dry eye disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.106020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106020"}}